Table 1 Baseline characteristics at ETI initiation visit.
Men (n = 133) | Women (n = 87) | p | |
|---|---|---|---|
Age (years, median [Q1;Q3]) | 29.7 [23.9; 37.3] | 28.5 [23.2; 35.2] | 0.15 |
Genotype F508del homozygote (n, %) F508del heterozygote (n, %) Other genotypes (n, %) | 77 (57.9%) 55 (41.4% 1 (0.8%) | 49 (56.3%) 37 (42.5%) 1 (1.1%) | 0.95 |
BMI (kg.m− 2, median [Q1;Q3]) | 21.2 [19.4; 23.4] | 20.0 [18.6; 21.9] | 0.27 |
Diabetes (n, %) | 26 (19.7%) | 25 (29.4%) | 0.09 |
PPI use (n, %) | 52 (39.4%) | 32 (37.6%) | 0.79 |
Pseudomonas aeruginosa positivity (n, %) | 86 (64%) | 57 (65%) | 0.96 |
Haemoglobin (g/dL, median [Q1;Q3]) | 15.1 [14.5; 15.8] | 12.9 [12.2; 14] | < 0.001 |
Anaemia (n, %) | 7 (5.4%) | 20 (24.1%) | < 0.001 |
Iron deficiency (n, %) | 59 (44%) | 68 (78%) | < 0.001 |
Ferritin (µg/L, median [Q1;Q3]) | 63 [35; 110] | 27.5 [14; 53] | < 0.001 |
TSAT (%) | 21 [15; 26] | 14 [9; 18] | < 0.001 |
CRP (mg/L) | 5 [1.8; 11.1] | 5.7 [2.3; 16.5] | 0.14 |
FEV1p (median [Q1;Q3] | 66 [50; 81] | 52.5 [40; 72.3] | < 0.001 |
FEV1 (n, %) - > 69% - 50–69% - 30–49% - < 30% | 57 (44.2%) 40 (31%) 28 (21.7%) 4 (3.1%) | 25 (29.8%) 20 (23.8%) 33 (39.3%) 6 (7.1%) | 0.01 |
